From the helm: Cyclopharm’s (ASX:CYC) MD & CEO, James McBrayer

Jessica Amir
February 5, 2021

In this instalment of our From the helm series, Bell Direct’s Jessica Amir speaks to Cyclopharm’s (ASX:CYC) MD & CEO, James McBrayer.

Cyclopharm is a little known Aussie company. Its medical technology is used in 60 countries around the world to help doctors identify lung capacity, as well as find potential blood clots. With earnings mostly coming from Europe, CYC’s US journey gathers momentum with USFDA approval looming. The US is home to the world’s largest nuclear medicine market.

In this video James discusses:

  • (0:31) What CYC does & its “imminent” entry into the US
  • (1:11) Key catalysts to drive share price growth – (1:47) Commercialising the product in the US
  • (2:46) CYC’s product being endorsed to help fight COVID-19 in the US – (3:31) How the company has reduced its risks
  • (4:56) After a 110% rise in share price last year, what can investors expect for the year ahead?

Weekly Wrap 3 December

Sophia Mavridis
December 3, 2021

Morning Bell 2 December

Paulina Peters
December 2, 2021

Morning Bell 1 December

Sophia Mavridis
December 1, 2021

Morning Bell 30 November

Paulina Peters
November 30, 2021

Morning Bell 29 November

Sophia Mavridis
November 29, 2021

Weekly Wrap 26 November

Sophia Mavridis
November 26, 2021

Morning Bell 25 November

Paulina Peters
November 25, 2021

Morning Bell 24 November

Sophia Mavridis
November 24, 2021

Morning Bell 23 November

Paulina Peters
November 23, 2021

Morning Bell 22 November

Sophia Mavridis
November 22, 2021

Weekly Wrap 19 November

Sophia Mavridis
November 19, 2021

Morning Bell 18 November

Paulina Peters
November 18, 2021